hce (Q81083): Difference between revisions
From MaRDI portal
Removed claim: copyright license (P163): MIT license (Q56842) |
Added link to MaRDI item. |
||||||||||||||
(9 intermediate revisions by 2 users not shown) | |||||||||||||||
Property / last update | |||||||||||||||
| |||||||||||||||
Property / last update: 16 January 2023 / rank | |||||||||||||||
Property / copyright license | |||||||||||||||
Property / copyright license: File License / rank | |||||||||||||||
Property / copyright license: File License / qualifier | |||||||||||||||
Property / imports | |||||||||||||||
Property / imports: base / rank | |||||||||||||||
Property / imports | |||||||||||||||
Property / imports: stats / rank | |||||||||||||||
Property / cites work | |||||||||||||||
Property / cites work: Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial / rank | |||||||||||||||
Property / depends on software | |||||||||||||||
Property / depends on software: R / rank | |||||||||||||||
Property / software version identifier | |||||||||||||||
0.0.2 | |||||||||||||||
Property / software version identifier: 0.0.2 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / software version identifier: 0.0.2 / qualifier | |||||||||||||||
publication date: 26 September 2022
| |||||||||||||||
Property / software version identifier | |||||||||||||||
0.0.8 | |||||||||||||||
Property / software version identifier: 0.0.8 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / software version identifier: 0.0.8 / qualifier | |||||||||||||||
publication date: 16 November 2022
| |||||||||||||||
Property / software version identifier | |||||||||||||||
0.4.0 | |||||||||||||||
Property / software version identifier: 0.4.0 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / software version identifier: 0.4.0 / qualifier | |||||||||||||||
publication date: 5 January 2023
| |||||||||||||||
Property / software version identifier | |||||||||||||||
0.5.8 | |||||||||||||||
Property / software version identifier: 0.5.8 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / software version identifier: 0.5.8 / qualifier | |||||||||||||||
publication date: 17 August 2023
| |||||||||||||||
Property / software version identifier | |||||||||||||||
0.5.9 | |||||||||||||||
Property / software version identifier: 0.5.9 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / software version identifier: 0.5.9 / qualifier | |||||||||||||||
publication date: 31 October 2023
| |||||||||||||||
Property / last update | |||||||||||||||
31 October 2023
| |||||||||||||||
Property / last update: 31 October 2023 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / description | |||||||||||||||
Simulate and analyze hierarchical composite endpoints. Win odds is the main analysis method. See Gasparyan SB et al (2022) "Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial." Therapeutic Innovation & Regulatory Science 56: 785–794. <doi:10.1007/s43441-022-00420-1>. | |||||||||||||||
Property / description: Simulate and analyze hierarchical composite endpoints. Win odds is the main analysis method. See Gasparyan SB et al (2022) "Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial." Therapeutic Innovation & Regulatory Science 56: 785–794. <doi:10.1007/s43441-022-00420-1>. / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / author | |||||||||||||||
Property / author: Samvel B. Gasparyan / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / copyright license | |||||||||||||||
Property / copyright license: MIT license / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / copyright license | |||||||||||||||
Property / copyright license: File License / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / copyright license: File License / qualifier | |||||||||||||||
Property / imports | |||||||||||||||
Property / imports: base / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / imports | |||||||||||||||
Property / imports: stats / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / cites work | |||||||||||||||
Property / cites work: Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / depends on software | |||||||||||||||
Property / depends on software: R / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / depends on software: R / qualifier | |||||||||||||||
software version identifier: ≥ 2.10 | |||||||||||||||
Property / MaRDI profile type | |||||||||||||||
Property / MaRDI profile type: MaRDI software profile / rank | |||||||||||||||
Normal rank | |||||||||||||||
links / mardi / name | links / mardi / name | ||||||||||||||
Latest revision as of 18:56, 12 March 2024
Design and Analysis of Hierarchical Composite Endpoints
Language | Label | Description | Also known as |
---|---|---|---|
English | hce |
Design and Analysis of Hierarchical Composite Endpoints |
Statements
31 October 2023
0 references
Simulate and analyze hierarchical composite endpoints. Win odds is the main analysis method. See Gasparyan SB et al (2022) "Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial." Therapeutic Innovation & Regulatory Science 56: 785–794. <doi:10.1007/s43441-022-00420-1>.
0 references